TY - JOUR
T1 - Managing GIST in the imatinib era
T2 - Optimization of adjuvant therapy
AU - Trent, Jonathan C.
AU - Subramanian, Meenakshi P.
N1 - Funding Information:
JC Trent serves on advisory boards for Novartis, Pfizer, and GlaxoSmithKline and serves as a speaker for Novartis, Pfizer, and GlaxoSmithKline. MP Subramanian is an employee of Evidence Scientific Solutions. Medical writing support was provided by SJ Slater and L Rosenberg, CMPP of Evidence Scientific Solutions, which was supported by Novartis Pharmaceuticals Corporation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© Informa UK, Ltd.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - We reviewed studies evaluating the clinical benefits of 1 year or more of adjuvant imatinib therapy in patients with gastrointestinal stromal tumor (GIST). Data from the Scandinavian Sarcoma Group (SSG) XVIII/AIO Phase III trial of 1 year versus 3 years of adjuvant imatinib support the use of 3 years as standard of care in patients who are at high risk for GIST recurrence following resection. Although adjuvant imatinib therapy prolonged recurrence-free survival in the evaluated trials, overall survival was not significantly increased except in the SSG XVIII/AIO trial. The optimal duration of therapy, and whether high-risk patients should use adjuvant imatinib continuously, remains unknown. The importance of risk assessment, risk stratification and GIST genotype in patient selection is also discussed.
AB - We reviewed studies evaluating the clinical benefits of 1 year or more of adjuvant imatinib therapy in patients with gastrointestinal stromal tumor (GIST). Data from the Scandinavian Sarcoma Group (SSG) XVIII/AIO Phase III trial of 1 year versus 3 years of adjuvant imatinib support the use of 3 years as standard of care in patients who are at high risk for GIST recurrence following resection. Although adjuvant imatinib therapy prolonged recurrence-free survival in the evaluated trials, overall survival was not significantly increased except in the SSG XVIII/AIO trial. The optimal duration of therapy, and whether high-risk patients should use adjuvant imatinib continuously, remains unknown. The importance of risk assessment, risk stratification and GIST genotype in patient selection is also discussed.
KW - adjuvant drug therapy
KW - gastrointestinal stromal tumor
KW - GIST
KW - imatinib mesylate
KW - mutational analysis
UR - http://www.scopus.com/inward/record.url?scp=84911897971&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84911897971&partnerID=8YFLogxK
U2 - 10.1586/14737140.2014.952284
DO - 10.1586/14737140.2014.952284
M3 - Review article
C2 - 25340579
AN - SCOPUS:84911897971
VL - 14
SP - 1445
EP - 1459
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 12
ER -